Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“There is increasing evidence suggesting that the pathogenesis of Alzheimer’s disease is not restricted to amyloid-b plaques and tau tangles but also includes strong interactions with immunological mechanisms.(1) In line with this, astrocyte reactivity or astrocytosis is a well-known pathological process that is common…”
BackgroundMethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationAshton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436
Self-citationEmerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
Alzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353
Self-citationBlood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 351
Self-citationBellaver, B., Povala, G., Ferreira, P. C. L., Ferrari-Souza, J. P., Leffa, D. T., Lussier, F. Z., Benedet, A. L., Ashton, N. J., Triana-Baltzer, G., Kolb, H. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02380-x · Cited by 319
Self-citationChatterjee, P., Pedrini, S., Doecke, J. D., Thota, R., Villemagne, V. L., Doré, V., Singh, A. K., Wang, P., Rainey‐Smith, S., Fowler, C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12724 · Cited by 312
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
“To determine the accuracy of blood GFAP in discriminating between individuals who are PET positive and those who are PET negative using specific A β , the area under the curve (AUC) was calculated and ranged from 0.69 to 0.86, indicating GFAP’s greater discriminatory power [32,42,53].”
MethodInfluentialPontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3392 · Cited by 261
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease
Chatterjee, P., Pedrini, S., Ashton, N. J., Tegg, M., Goozee, K., Singh, A. K., Karikari, T. K., Simrén, J., Vanmechelen, E., Armstrong, N. J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12447 · Cited by 231
Self-citationPichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12787 · Cited by 226
Self-citationSpecific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205
“Contrarily, previous studies have shown significant associations between this marker and amyloid pathology (as measured by CSF or PET), which were stronger than those with tau pathology (also measured with CSF or PET; Benedet et al , 2021; Pereira et al , 2021).”
ResultSelf-citationHead‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
(2024) · doi:10.1002/alz.14315 · Cited by 199
Self-citationPais, M. V., Forlenza, O. V., & Diniz, B. S. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230029 · Cited by 156
Baiardi, S., Quadalti, C., Mammana, A., Dellavalle, S., Zenesini, C., Sambati, L., Pantieri, R., Polischi, B., Romano, L., Suffritti, M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01093-6 · Cited by 193
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
Palmqvist, S., Stomrud, E., Cullen, N., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12751 · Cited by 166
Self-citationExercise suppresses neuroinflammation for alleviating Alzheimer’s disease
Wang, M., Zhang, H., Liang, J., Huang, J., & Chen, N. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02753-6 · Cited by 162
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 162
Self-citationPredicting amyloid PET and tau PET stages with plasma biomarkers
Jack, C. R., Wiste, H. J., Algeciras-Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 147
Frontera, J. A., Boutajangout, A., Masurkar, A. V., Betensky, R. A., Ge, Y., Vedvyas, A., Debure, L., Moreira, A., Lewis, A., Huang, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12556 · Cited by 139
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Benedet, A. L., Brum, W. S., Hansson, O., Initiative, A. D. N., Karikari, T. K., Zimmer, E. R., Zetterberg, H., Blennow, K., & Ashton, N. J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00942-0 · Cited by 138
Self-citationAstrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
Ferrari-Souza, J. P., Ferreira, P. C. L., Bellaver, B., Tissot, C., Wang, Y.-T., Leffa, D. T., Brum, W. S., Benedet, A. L., Ashton, N. J., De Bastiani, M. A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01716-2 · Cited by 139
Self-citationShir, D., Graff‐Radford, J., Hofrenning, E. I., Lesnick, T. G., Przybelski, S. A., Lowe, V. J., Knopman, D. S., Petersen, R. C., Jack, C. R., Vemuri, P., et al. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12291 · Cited by 121
Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer’s disease
Kumar, A., Fontana, I. C., & Nordberg, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15565 · Cited by 150
Frontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 145
Janelidze, S., Barthélemy, N. R., Salvadó, G., Schindler, S. E., Palmqvist, S., Mattsson, N., Braunstein, J. B., Ovod, V., Bollinger, J. G., He, Y., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2619 · Cited by 144
Self-citationPeripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
Wang, X., Shi, Z., Qiu, Y., Sun, D., & Zhou, H. (2024) · BMC Medicine · doi:10.1186/s12916-024-03418-8 · Cited by 141
Staging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
Jonaitis, E. M., Janelidze, S., Cody, K. A., Langhough, R., Du, L., Chin, N. A., Mattsson-Carlgren, N., Hogan, K. J., Christian, B. T., Betthauser, T. J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad057 · Cited by 124
Self-citationAstrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression
Pelkmans, W., Shekari, M., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Minguillón, C., Fauria, K., Molinuevo, J. L., Grau‐Rivera, O., González Escalante, A., Kollmorgen, G., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13450 · Cited by 122
Self-citationChong, J. R., Ashton, N. J., Karikari, T. K., Tanaka, T., Schöll, M., Zetterberg, H., Blennow, K., Chen, C., & Lai, M. K. P. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327370 · Cited by 115
Self-citationHeimfarth, L., Passos, F. R. S., Monteiro, B. S., Araújo, A. A. D. S., Quintans‐Júnior, L. J., & Quintans, J. D. S. S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108624 · Cited by 115
Post-acute blood biomarkers and disease progression in traumatic brain injury
Newcombe, V., Ashton, N. J., Posti, J. P., Glocker, B., Manktelow, A. E., Chatfield, D. A., Winzeck, S., Needham, E., Correia, M., Williams, G. B., et al. (2022) · Brain · doi:10.1093/brain/awac126 · Cited by 114
Self-citationSánchez‐Juan, P., Valeriano-Lorenzo, E., Ruiz-González, A., Pastor, A. B., Lara, H. R., López-González, F., Zea‐Sevilla, M. A., Valentí, M., Payo, B. F., Ruiz, P., et al. (2024) · Brain · doi:10.1093/brain/awae035 · Cited by 108
Ashton, N. J., Keshavan, A., Brum, W. S., Andréasson, U., Arslan, B., Droescher, M., Barghorn, S., Vanbrabant, J., Lambrechts, C., Loo, M. V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14508 · Cited by 108
Self-citationHeneka, M. T., Gauthier, S. G., Chandekar, S. A., Hahn-Pedersen, J. H., Bentsen, M. A., & Zetterberg, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02939-9 · Cited by 108
Self-citationRecent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Cohen, J., Mathew, A., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., et al. (2024) · Cells · doi:10.3390/cells13060511 · Cited by 103
“Another study suggested that significantly increased plasma GFAP level as an early marker for brain A β pathology and astrocytosis, but not tau aggregation in AD pathogenesis [37].”
BackgroundLongitudinal blood biomarker trajectories in preclinical Alzheimer's disease
Yakoub, Y., Ashton, N. J., Strikwerda‐Brown, C., Montoliu‐Gaya, L., Karikari, T. K., Kac, P. R., González‐Ortiz, F., Gallego-Rudolf, J., Meyer, P., St‐Onge, F., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13318 · Cited by 102
Self-citationChatterjee, P., Vermunt, L., Gordon, B. A., Pedrini, S., Boonkamp, L., Armstrong, N. J., Xiong, C., Singh, A. K., Li, Y., Sohrabi, H. R., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12879 · Cited by 81
Self-citationGlial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A., Lehmann, S., & Hirtz, C. (2024) · Brain Communications · doi:10.1093/braincomms/fcae396 · Cited by 101
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Arslan, B., Zetterberg, H., & Ashton, N. J. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1434 · Cited by 97
Self-citationZeng, X., Lafferty, T. K., Sehrawat, A., Chen, Y., Ferreira, P. C. L., Bellaver, B., Povala, G., Kamboh, M. I., Klunk, W. E., Cohen, A. D., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00753-5 · Cited by 98
Longitudinal changes in Alzheimer's‐related plasma biomarkers and brain amyloid
Bilgel, M., An, Y., Walker, K. A., Moghekar, A., Ashton, N. J., Kac, P. R., Karikari, T. K., Blennow, K., Zetterberg, H., Jedynak, B., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13157 · Cited by 95
Self-citationThe dynamics of plasma biomarkers across the Alzheimer’s continuum
Guo, Y., Shen, X.-N., Wang, H.-F., Chen, S.-D., Zhang, Y.-R., Chen, S.-F., Cui, M., Cheng, W., Dong, Q., Ma, T., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01174-0 · Cited by 95
Yu, L., Boyle, P. A., Janelidze, S., Petyuk, V., Wang, T., Bennett, D. A., Hansson, O., & Schneider, J. A. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02570-4 · Cited by 94
Self-citationZeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S., Sweet, R. A., Tudorascu, D. L., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 94
Self-citationCullen, N. C., Janelidze, S., Mattsson‐Carlgren, N., Palmqvist, S., Bittner, T., Suridjan, I., Jethwa, A., Kollmorgen, G., Brum, W. S., Zetterberg, H., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12706 · Cited by 84
Self-citationZhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00275-w · Cited by 86
“In line with other reports in AD patients [16, 20, 22], we observed that pGFAP predicted faster cognitive decline both in FTD and AD.”
ResultPlasma biomarker profiles in autosomal dominant Alzheimer’s disease
Johansson, C., Thordardottir, S., Laffita-Mesa, J., Rodriguez-Vieitez, E., Zetterberg, H., Blennow, K., & Graff, C. (2023) · Brain · doi:10.1093/brain/awac399 · Cited by 74
Self-citationKivisäkk, P., Sweeney, T., Carlyle, B. C., Trombetta, B. A., LaCasse, K., El‐Mufti, L. H., Tuncali, I., Chibnik, L. B., Das, S., Scherzer, C. R., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1069411 · Cited by 85
Simrén, J., Weninger, H., Brum, W. S., Khalil, S., Benedet, A. L., Blennow, K., Zetterberg, H., & Ashton, N. J. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12806 · Cited by 80
Self-citationLista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81
“The study found that plasma GFAP levels were associated with both longitudinal Aβ-PET deposition and cognitive decline [113].”
BackgroundDevelopment of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 81
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Prins, S., de Kam, M. L., Teunissen, C. E., & Groeneveld, G. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01051-2 · Cited by 82
Self-citationZou, B., Li, J., Ma, R., Cheng, X.-Y., Ma, R.-Y., Zhou, T.-Y., Wu, Z., Yao, Y., & Li, J. (2023) · Aging and Disease · doi:10.14336/ad.2022.1127 · Cited by 80
Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
Brum, W. S., Ashton, N. J., Simrén, J., di Molfetta, G., Karikari, T. K., Benedet, A. L., Zimmer, E. R., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Jeromin, A., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13518 · Cited by 76
Self-citationLin, J., Ou, R., Li, C., Hou, Y., Zhang, L., Wei, Q., Pang, D., Liu, K., Jiang, Q., Yang, T., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03120-1 · Cited by 79
Developments in scalable strategies for detecting early markers of cognitive decline
Whelan, R., Barbey, F. M., Cominetti, M. R., Gillan, C. M., & Rosická, A. M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02237-w · Cited by 77
Eide, P. K., Lashkarivand, A., Pripp, A. H., Valnes, L. M., Hovd, M. H., Ringstad, G. A., Blennow, K., & Zetterberg, H. (2023) · Nature Communications · doi:10.1038/s41467-023-37685-5 · Cited by 78
Self-citationNeuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
Blood-based biomarkers of cerebral small vessel disease
Wu, L., Chai, Y. L., Cheah, I. K.-M., Chia, R. S. L., Hilal, S., Arumugam, T. V., Chen, C., & Lai, M. K. P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102247 · Cited by 73
Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline
Peretti, D. E., Boccalini, C., Ribaldi, F., Scheffler, M., Marizzoni, M., Ashton, N. J., Zetterberg, H., Blennow, K., Frisoni, G. B., & Garibotto, V. (2024) · Brain · doi:10.1093/brain/awae211 · Cited by 72
Self-citationVandeVrede, L. A., Cho, H., Sanderson‐Cimino, M. E., Wekselman, F., Cobigo, Y., Gorno‐Tempini, M. L., Heuer, H. W., Kramer, J. H., Lago, A. L., Leichter, D., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2024.5017 · Cited by 69
Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives
Huang, S., Wang, Y., & Guo, J. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00836-7 · Cited by 67
Blood Biomarkers of Alzheimer’s Disease and Cognition: A Literature Review
García‐Escobar, G., Manero, R. M., Fernández‐Lebrero, A., Ois, Á., Navalpotro‐Gómez, I., Puente, V., Muñana, J. C., Estragués-Gázquez, I., Puig‐Pijoan, A., & Jiménez-Baladó, J. (2024) · Biomolecules · doi:10.3390/biom14010093 · Cited by 67
Plasma biomarkers for neurodegenerative disorders: ready for prime time?
Balogun, W. G., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000851 · Cited by 66
Self-citationLiu, T., Zuo, H., Ma, D., Song, D., Zhao, Y., & Cheng, O. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02843-5 · Cited by 66
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges
Delaby, C., Hirtz, C., & Lehmann, S. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.09.003 · Cited by 64
Microglial activation as a hallmark of neuroinflammation in Alzheimer’s disease
Ebrahimi, R., Nejad, S. S., Tafti, M. F., Karimi, Z., Sadr, S. R., Hussein, D. R., Talebian, N., & Esmaeilpour, K. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01631-9 · Cited by 63
Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer’s Disease
Nadeem, M. S., Hosawi, S. B. I., Alshehri, S., Ghoneim, M. M., Imam, S. S., Murtaza, B. N., & Kazmi, I. A. (2021) · Biomolecules · doi:10.3390/biom11111635 · Cited by 63
Testosterone, cognitive decline and dementia in ageing men
Yeap, B. B., & Flicker, L. A. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09728-7 · Cited by 62
Montoliu‐Gaya, L., Alcolea, D. A., Ashton, N. J., Pegueroles, J., Levin, J., Bosch, B., Lantero‐Rodriguez, J., Carmona‐Iragui, M., Wagemann, O., Balasa, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104547 · Cited by 62
Self-citationZetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 61
Self-citationDetection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
Janelidze, S., Christian, B. T., Price, J., Laymon, C., Schupf, N., Klunk, W. E., Lott, I., Silverman, W., Rosas, H. D., Zaman, S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1740 · Cited by 60
Self-citationBlood Biomarkers for Alzheimer’s Disease in Down Syndrome
Montoliu‐Gaya, L., Strydom, A., Blennow, K., Zetterberg, H., & Ashton, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163639 · Cited by 60
Self-citationBolsewig, K., van Unnik, A. A. J. M., Blujdea, E. R., González, M. C., Ashton, N. J., Aarsland, D., Zetterberg, H., Padovani, A., Bonanni, L., Mollenhauer, B., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209418 · Cited by 59
Self-citationBlood biomarkers for Alzheimer's disease and related disorders
Zetterberg, H., & Schott, J. M. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13628 · Cited by 59
Self-citationFluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Self-citationMicroglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease
Ferrari‐Souza, J. P., Povala, G., Rahmouni, N., Bellaver, B., Ferreira, P. C. L., Bastiani, M. A. D., Leffa, D. T., Lussier, F. Z., Aguzzoli, C. S., Brum, W. S., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02103-0 · Cited by 60
Self-citationHippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies
De Bastiani, M. A., Bellaver, B., Brum, W. S., Souza, D. G., Ferreira, P. C. L., Rocha, A. S., Povala, G., Ferrari-Souza, J. P., Benedet, A. L., Ashton, N. J., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.03.001 · Cited by 57
Self-citationHuber, H., Blennow, K., Zetterberg, H., Boada, M., Jeromin, A., Weninger, H., Núñez‐Llaves, R., Aguilera, N., Ramis, M., Simrén, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13697 · Cited by 57
Self-citationAlzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
Pichet Binette, A., Palmqvist, S., Bali, D., Farrar, G., Buckley, C. J., Wolk, D. A., Zetterberg, H., Blennow, K., Janelidze, S., & Hansson, O. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00990-0 · Cited by 52
Self-citationMeasures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
Spotorno, N., Strandberg, O. T., Vis, G., Stomrud, E., Nilsson, M., & Hansson, O. (2022) · Brain · doi:10.1093/brain/awac343 · Cited by 56
Self-citationCronjé, H. T., Liu, X., Odden, M. C., Moseholm, K. F., Seshadri, S. S., Satizábal, C. L., López, O. L., Bis, J. C., Djoussé, L., Fohner, A. E., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13367 · Cited by 56
Huber, H., Ashton, N. J., Schieren, A., Montoliu‐Gaya, L., Molfetta, G. D., Brum, W. S., Lantero‐Rodriguez, J., Grötschel, L., Stoffel‐Wagner, B., Coenen, M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13163 · Cited by 55
Self-citationPlasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals
Ferreira, P. C. L., Therriault, J., Tissot, C., Ferrari‐Souza, J. P., Benedet, A. L., Povala, G., Bellaver, B., Leffa, D. T., Brum, W. S., Lussier, F. Z., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13393 · Cited by 54
Self-citationChiotis, K., Johansson, C., Rodriguez‐Vieitez, E., Ashton, N. J., Blennow, K., Zetterberg, H., Graff, C., & Nordberg, A. K. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00647-y · Cited by 54
Self-citationAsken, B. M., Tanner, J. A., VandeVrede, L. A., Casaletto, K. B., Staffaroni, A. M., Mundada, N. S., Fonseca, C. S., Iaccarino, L., Joie, R. L., Tsuei, T., et al. (2022) · Journal of Neurotrauma · doi:10.1089/neu.2022.0060 · Cited by 54
A population‐based meta‐analysis of circulating GFAP for cognition and dementia risk
Gonzales, M. M., Wiedner, C. D., Wang, C., Liu, Q., Bis, J. C., Li, Z., Himali, J. J., Ghosh, S., Thomas, E. A., Parent, D. M., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51652 · Cited by 53
French, S. R., Meyer, B. P., Arias, J. C., Levendovszky, S. R., & Weinkauf, C. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70104 · Cited by 53
Gao, F., Dai, L., Wang, Q., Liu, C., Deng, K., Cheng, Z., Lv, X., Wu, Y., Zhang, Z., Tao, Q., et al. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.07.009 · Cited by 52
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
Milà‐Alomà, M., Tosun, D., Schindler, S. E., Hausle, I., Petersen, K. K., Li, Y., Dage, J. L., Du‐Cuny, L., Saad, Z. S., Saef, B. A., et al. (2025) · Annals of Neurology · doi:10.1002/ana.27285 · Cited by 52
Self-citationAstrocyte and oligodendrocyte pathology in Alzheimer's disease
Ziar, R., Tesar, P. J., & Clayton, B. L. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00540 · Cited by 50
Ferreira, P. C. L., Zhang, Y., Snitz, B. E., Chang, C. H., Bellaver, B., Jacobsen, E. P., Kamboh, M. I., Zetterberg, H., Blennow, K., Pascoal, T. A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12986 · Cited by 50
Self-citationMulti-omics analysis reveals the key factors involved in the severity of the Alzheimer’s disease
Meng, L., Jin, H., Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Coskun, E., Idil, E., Nogaylar, R., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01578-6 · Cited by 49
“Increased NEFL levels are associated with AD and other neurodegenerative disorders [10, 70], while GFAP is an early marker of Aβ pathology in AD [54].”
Background
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.